CML Advocates Network and iCMLf join forces on Paediatric CML on International Childhood Cancer Day
The "CML Advocates Network", the international platform of patient groups supporting patients and relatives suffering from Chronic Myeloid Leukaemia, and the International CML Foundation join forces to support young patients affected by that rare form of leukaemia, as well as physicians and researchers. The project, launched on International Childhood Cancer Day on 15 February 2011, will encompass a range of activities to support collaboration and sharing of experience of parents of young patients as well as physicians treating children with this ultra-rare condition.
1 comments
World Cancer Day 2011, Maximized: The Max Foundation submits 13.000 signatures to World Cancer Declaration
A delegation representing the Max Foundation's Maximize Life Movement arrived in Geneva on World Cancer Day (4 Feb 2011) and delivered 13,000 signatures endorsing the World Cancer Declaration to the Union for International Cancer Control (UICC). On behalf of 30 patient associations as well as volunteers and committed individuals in 87 countries, the five delegates brought with them the spirit and energy of everyone who embraces the Maximize Life Movement. Read more here
"CML Advocates Network" now connects 59 leukaemia patient groups in 48 countries
ASH 2010 Report: A new era in first line CML treatment coming up?
Like every year, about 30.000 physicians, researchers and industry representatives from all across the world met in the US to discuss groundbreaking news in leukemias and other hematologic diseases. While "the ASH" is designed to be a meeting exclusively for health professionals, about 30 patient advocates representing patients with e.g. CML, myeloma and lymphoma attended to follow, discuss and disseminate the news.
iCMLf-ESH Meeting in Washington DC: A patient's perspective
[Languages: English | Russian]From 24-26 September 2010, the iCMLf-ESH conference on Chronic Myeloid Leukemia (CML) brought together around 400 CML experts from all across the world in Washington DC. Speakers and audience discussed the biological mechanisms of the disease and its treatment, and also about news from clinical trials with 3rd generation therapies.
